Ambrx and NovoCodex form Second Collaboration to Develop and Commercialize Ambrx’s Antibody Drug Conjugates

SAN DIEGO and SHANGHAI, October 22, 2019 /PRNewswire/ — Ambrx and NovoCodex Biopharmaceuticals Ltd., (NovoCodex), a majority owned company of Zhejiang Medicine Co Ltd., today announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates (ADCs). Under the agreement, Ambrx and NovoCodex will join forces to continue the development of ARX305, an Ambrx enabled ADC for the treatment of CD70 positive cancers. Under the terms of the agreement, NovoCodex is responsible for developing and commercializing ARX305 in China while Ambrx is responsible for developing and commercializing ARX305 outside of China. NovoCodex will fund global development activities to the end of Phase 1 clinical trials and pay Ambrx an undisclosed upfront payment, development milestones, and a double digit royalty on product sales in China. NovoCodex is also eligible to share in undisclosed portion of ARX305 product sales outside of China. “We are excited to initiate our second collaboration with NovoCodex following our successful collaboration with ARX788, which is currently in Phase 1 clinical trials for HER2 positive breast and gastric cancers. ARX305 is a natural extension to the first collaboration with the inclusion of another Ambrx enabled ADC that is intended to treat CD70 positive cancers such as Renal Cell Carcinoma and Multiple Myeloma. Further, we continue to align ourselves with China’s leading pharmaceutical companies” said Feng Tian, Ph.D., Chief Executive Officer of Ambrx. “ARX305, which is expected to start Phase 1 clinical trials in early 2021, allows Ambrx to expand its ADC pipeline into multiple cancer types while gaining access to the China market through our partnership with NovoCodex.” Chunbo...

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients

SAN DIEGO, March 21, 2016 – Ambrx and Zhejiang Medicine Co. Ltd. (ZMC) announced today that they initiated First-In-Human phase I clinical trial with ARX788, Ambrx’s most advanced internally developed site-specific antibody drug conjugate (ADC) targeting Her2. Ambrx ARX788 may hold the potential for a broader patient population than the currently available Her2 targeting therapies. The multicenter study will be conducted at several sites within Australia and New Zealand. The primary end point is safety and tolerability, and the pharmacokinetics of ARX788 will also be evaluated. The application for the initiation of clinical trial in China was submitted to the China FDA early this year. Ambrx and Zhejiang Medicine Co. Ltd entered into collaboration on June 14, 2013 to develop ARX788 into a world class standard in China. Zhejiang receives commercial rights in China while Ambrx retains commercial rights outside of China. WuXi Apptec provided preclinical services and successfully manufactured Ambrx site-specific ADC under CGMP regulation. “We are very happy about the collaboration with ZMC. This is an important milestone for this partnership,” said Alex Qiao, Chief Executive Office at Ambrx. “This is the first exciting step to demonstrate the clinical application of our proprietary EuCODE™ technology for the improvements of cancer patient lives. This is not only an important milestone for our ARX788 program, but also is a major event for our unique site specific protein conjugation technology platform as we hope to leverage this same technology to develop ADC drugs for a number of different cancers.” “We are very happy to see ARX788 entering into clinical trial,” Said Mr. Chunbo Li, chairman of ZMC. “We hope our collaboration...

Ambrx Announces New Chief Medical Officer

SAN DIEGO, Nov. 16, 2015  Ambrx today announced the appointment of Yong-Jiang Hei, M.D., Ph.D. as Chief Medical Officer (CMO) reporting directly to CEO, Tiecheng “Alex” Qiao. With nearly 20 years of experience in pharmaceuticals and biotechnology, Dr. Hei brings to Ambrx broad knowledge and tremendous expertise in oncology clinical development as well as medical affairs.  Prior to Ambrx, Dr. Hei worked at Amgen for more than 9 years as an Executive Medical Director in global development where he led cross-functional teams to define product development strategies and clinical development plans for several late-phase oncology projects in various solid tumors.  He drove the design and execution of multiple clinical trials including a large randomized international phase 3 trial in non-small cell lung cancer (NSCLC).  Additionally, Dr. Hei spent three years in China as the medical head for Amgen China to build and establish a talented clinical medical team for Amgen China affiliate.  Before Amgen, Dr. Hei worked for Roche Laboratories, Inc., and Novartis oncology with increasing responsibilities in the capacity of US Medical Director for Roche, and Senior Global Brand Medical Director/Executive Director for Novartis Oncology where he led the development and execution of medical plans, expanded the investigator-initiated clinical research, and supported regulatory filings in the US, Japan, the EMEA, and China.  Dr. Hei received his medical degree from Shihezi Medical College in China, and graduate degrees from the West China University of Medical Sciences (M.Sc) and the University of British Columbia in Canada (Ph.D.).  He also trained in the Hospital for Sick Children in Toronto as a post-doctoral fellow in cancer biology.  “We are thrilled to have attracted...

Ambrx Names Dr. Tiecheng Qiao as CEO, Dr. Feng Tian as CSO

Ambrx Names Dr. Tiecheng Qiao as CEO, Dr. Feng Tian as CSO Executives Will Work With New Chinese Owners to Advance Technology and Product Pipeline San Diego, June 19, 2015 — Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates, today announced the appointment of Dr. Tiecheng (Alex) Qiao as CEO, effective immediately. Ambrx also announced that Dr. Feng Tian, formerly vice president of science and technology, China, has been promoted to the newly-created position of chief science officer, effective immediately.  Dr. Tian will report directly to Dr. Qiao. The appointments come as Ambrx marks an important milestone.  On June 17, 2015, Ambrx closed a merger with a Chinese consortium consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund, and WuXi PharmaTech. The merger combines the resources of leading China-based life science companies and investors with a leading U.S.-based innovator in biologics development. With the agreement now in place, Ambrx has additional resources to advance the technology and product pipeline under development in its U.S. research center and to build a new global product development center in China. “Drs. Qiao and Tian are ideally qualified to lead Ambrx,” said Bing Li, a member of Ambrx’s board of directors. Dr. Qiao has founded and managed companies with U.S. and China technology operations, and Dr. Tian has a deep knowledge of Ambrx  and has acquired over 10-plus years of increasing responsibility for the company’s technology development.” Dr. Qiao has over 15 years of experience as an entrepreneur and senior manager in the life...

Chinese Consortium Enters into Agreement to Acquire Ambrx

SHANGHAI, May 21, 2015 /PRNewswire/ — A consortium (the “Consortium”) consisting of entities affiliated with Shanghai Fosun Pharmaceutical Group, HOPU Investments, China Everbright Limited’s healthcare fund (“CEL Healthcare Fund”), and WuXi PharmaTech announced today that the Consortium has signed a merger agreement pursuant to which the Consortium will acquire Ambrx Inc. The transaction is expected to close in the second quarter of 2015, subject to receipt of certain regulatory approvals and satisfaction of customary closing conditions. Other details of the transaction were not disclosed.Ambrx is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. The company’s proprietary technology platforms enable attachment of pharmaceutically active molecules to specific sites within proteins more precisely than prior generations of bio-conjugates and with precision similar to that used to design small-molecule drugs. Ambrx has developed a pipeline of novel product candidates that include antibody-drug conjugates, or ADCs, bi- and multi-specific drug conjugates, and long-acting therapeutic proteins. ADCs are expected to be one of the most important areas of monoclonal antibody development in the next decade, especially in targeted therapies for oncology, an area where Ambrx has a strong internal pipeline. The company’s most advanced internally developed product is ARX788, a site-specific ADC targeting Her2-positive breast cancer that Ambrx expects to begin clinical trials on in 2015. In addition to its internal pipeline, Ambrx collaborates with leading pharmaceutical companies, including Bristol-Myers Squibb, Merck, Eli Lilly, and Agensys. Ambrx’s most advanced collaboration product candidate in human health is ARX618, a long-acting fibroblast growth factor 21 for type 2 diabetes, for which collaboration partner Bristol-Myers Squibb is conducting Phase...